Omeros (NASDAQ:OMER) Stock Price Down 5.4%

Omeros Co. (NASDAQ:OMER) traded down 5.4% on Friday . The stock traded as low as $14.58 and last traded at $14.65, 679,741 shares changed hands during trading. An increase of 29% from the average session volume of 525,576 shares. The stock had previously closed at $15.49.

Several equities analysts have recently weighed in on the company. Wedbush set a $19.00 target price on Symantec and gave the company a “hold” rating in a research report on Monday. Zacks Investment Research downgraded H&E Equipment Services from a “hold” rating to a “sell” rating in a research report on Wednesday. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $71.00 price objective on shares of ExlService in a research report on Monday, May 6th. HC Wainwright set a $55.00 price objective on Acer Therapeutics and gave the company a “buy” rating in a research report on Tuesday, May 28th. Finally, ValuEngine downgraded Yirendai from a “sell” rating to a “strong sell” rating in a research report on Wednesday, June 26th. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $25.80.

The company has a market cap of $718.70 million, a PE ratio of -6.60 and a beta of 3.04. The company has a 50 day simple moving average of $16.10.

Omeros (NASDAQ:OMER) last issued its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.04). The company had revenue of $21.80 million during the quarter, compared to analysts’ expectations of $23.18 million. Omeros’s revenue was up 1271.1% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.62) EPS. On average, research analysts predict that Omeros Co. will post -1.68 EPS for the current year.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. First Trust Advisors LP bought a new position in Omeros in the 4th quarter valued at about $879,000. California Public Employees Retirement System increased its holdings in Omeros by 6.7% in the 4th quarter. California Public Employees Retirement System now owns 49,310 shares of the biopharmaceutical company’s stock valued at $549,000 after buying an additional 3,110 shares during the period. BlackRock Inc. increased its holdings in Omeros by 0.8% in the 4th quarter. BlackRock Inc. now owns 3,989,206 shares of the biopharmaceutical company’s stock valued at $44,439,000 after buying an additional 31,270 shares during the period. Bank of New York Mellon Corp increased its holdings in Omeros by 0.4% in the 4th quarter. Bank of New York Mellon Corp now owns 214,955 shares of the biopharmaceutical company’s stock valued at $2,394,000 after buying an additional 817 shares during the period. Finally, Geode Capital Management LLC increased its holdings in Omeros by 7.5% in the 4th quarter. Geode Capital Management LLC now owns 516,632 shares of the biopharmaceutical company’s stock valued at $5,755,000 after buying an additional 35,974 shares during the period. Hedge funds and other institutional investors own 52.12% of the company’s stock.

Omeros Company Profile (NASDAQ:OMER)

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.

Further Reading: What is the Bid-Ask Spread?

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.